Navigation Links
Antiretroviral treatment for preventing HIV infection: an evidence review for physicians
Date:5/28/2012

While immediate postexposure treatment for suspected HIV is critical, pre-exposure preventive treatment is a newer method that may be effective for people in high-risk groups, states a review of evidence published in CMAJ (Canadian Medical Association Journal).

"Although postexposure prophylaxis has a long history of success, newer methods such as pre-exposure prophylaxis and earlier treatment in the course of infection ("treatment as prevention") are being implemented with some success," writes Dr. Isaac Bogoch, Harvard Medical School and the Division of Infectious Diseases, Massachusetts General Hospital, Boston, with coauthors.

Several recent large randomized controlled trials have added to knowledge about pre-exposure prevention and early initiation of antiretroviral therapy. To provide physicians with current pharmacologic prevention methods, researchers from Massachusetts General Hospital, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts and Sunnybrook Health Sciences, Toronto conducted a review of literature from January 1990 to April 2012.

HIV is transmitted mainly through unprotected sex, contaminated needles and from mother to baby, although the latter transmission was not part of the review.

After assessing with a detailed history whether a person has been exposed to HIV, postexposure treatment (prophylaxis) should begin as soon as possible or within 72 hours and be continued for 28 days. If the patient is in a low-risk situation but not completely without risk, the physician and patient can decide upon the risks of transmission and whether to treat prophylactically. Current practice recommends a two-drug regimen of tenofovir with emtricitabine and a third drug in people with high-risk exposure.

"Evidence for quickly starting prophylaxis and a four-week duration of therapy stem from macaque models of transmission, in which starting prophylaxis later and shorter durations of
'/>"/>

Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-520-7116 x2224
Canadian Medical Association Journal
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Treating HIV-infected people with antiretrovirals significantly reduces transmission to partners
2. UNC-led study shows early treatment with antiretroviral therapy prevents HIV transmission
3. Antiretrovirals During Breast-Feeding Shield Babies From HIV, Study Shows
4. British experts update addiction treatment guidelines
5. VCU Massey Cancer Center sees potential in novel leukemia treatment
6. Correct treatment of common diabetic foot infections can reduce amputations
7. Biomarker predicts response to cancer treatment
8. First, do no harm: Study finds danger in standard treatment for a serious lung disease
9. Study examines treatments for relieving breathing difficulties among patients with lung effusions
10. Treatment of childhood OSA reverses brain abnormalities
11. Mount Sinai presents treatment trends, vaccine research, prognosis data at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , ... July 27, 2015 , ... ... Step One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 p.m. ... of the first things FDA investigators will look at during an inspection. ...
(Date:7/27/2015)... ... July 27, 2015 , ... On July 14, 2015, Harper’s Bazaar ... Issues,” describes common skin issues such as stretch marks , fine lines ... treat them. The treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal ...
(Date:7/27/2015)... ... July 27, 2015 , ... North Central Surgical Center Hospital will be holding ... all those prospective joint-replacement patients, along with their friends and family members, to attend. ... classes (Aug 6, Sept 8 [Tue due to Labor Day], Oct 5, Nov 2, ...
(Date:7/27/2015)... , ... July 27, 2015 , ... David Gilmour ... He will be performing for one additional night at each of his original four ... DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing ... to its options. Already an industry leader because of its use of ... for the latest successful trends in helping people to overcome addiction and live ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
... Most of the 28 million Americans living with untreated ... corrective action could result in the brain actually "forgetting" how ... , Dr. Beyer is senior vice president of HearUSA (Amex: ... hearing aids companies. , "When the brain is insufficiently stimulated ...
... Fla., Oct. 19 Blue Cross and ... statewide Medicare Advantage Regional PPO plan called BlueMedicare Regional ... offerings for Florida,s Medicare eligibles. The BlueMedicare Regional PPO ... Private Fee-for-Service, Part D and Medicare Supplement plans. , ...
... ... the world,s leading manufacturer and distributor of health testing stations and automated blood pressure ... with UnitedHealth Group,s Passport to Health and Well Being at the 2009 AARP Vegas@50+ ... ...
... ... Biodiagnostics, Inc., today announced that the U.S. Food and Drug Administration ... 15 monoclonal antibodies in its proprietary line of transfusion diagnostics. ... and hospitals to type and screen blood. Quotient Biodiagnostics was formed ...
... CITY, Kan., Oct. 19 Premier Plastic Surgery of Kansas City, ... has redesigned its extensive website to include a separate section ... and a Plastic Surgery Blog that features breaking news on ... Society for Aesthetic Plastic Surgery, cosmetic surgery for males increased ...
... and men have opposing views on many topics, and it ... pain. According to a new survey of women and men ... leading independent health information source for women, women are more ... have a higher tolerance for pain (76% versus 32%, respectively)(1).In ...
Cached Medicine News:Health News:If Hearing Loss is Not Treated, Brain Can 'Forget' How to Hear and Understand Speech 2Health News:Blue Cross and Blue Shield of Florida Now Offers More Choices to Florida's Seniors 2Health News:Blue Cross and Blue Shield of Florida Now Offers More Choices to Florida's Seniors 3Health News:Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 2Health News:Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 3Health News:Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market 2Health News:Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market 3Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 2Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 3Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 4Health News:Women and Men Face Off: Who Can Stand the Pain? 2Health News:Women and Men Face Off: Who Can Stand the Pain? 3
(Date:7/27/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of AMAG Pharmaceuticals Inc. ("AMAG" or ... advised to contact Peretz Bronstein or ... at info@bgandg.com or 212-697-6484. ... its officers and/or directors have violated Sections 10(b) ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4rvprn/ddimer_testing ) ... Testing Market - Global Industry Analysis, Size, Share, ... report to their offering. ... one of the fastest growing markets globally. This ... health care awareness, preference of the people for ...
(Date:7/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ... "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, ... report to their offering. ... on of assay type, therapeutic area, and geography. ... been categorized into six major segments: cAMP assays, ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Transplant Patients Represents First, Pivotal Study on a New Antiviral CMV Therapy in Stem Cell ... Over a Decade ... ... 29 ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal,Phase ...
... be Presented at ASCO Shows Survival Benefit in Complete ... Partial Responders Compared with Chemotherapy Alone, BERKELEY ... GNTA) announced the results of long-term,followup from a Phase ... sodium) Injection, in patients with chronic,lymphocytic leukemia (CLL). With ...
Cached Medicine Technology:ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 2ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 3ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 4ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 5ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 6Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 2Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 3Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 4
Bone Curette, 160 mm...
Bone Currettes...
London Endocervical Curette is a stainless-steel curette for obtaining endocervical samples with minimal effort....
...
Medicine Products: